{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T11:55:57Z","timestamp":1783338957886,"version":"3.54.6"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,3,6]]},"DOI":"10.7759\/cureus.22903","type":"journal-article","created":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T02:34:03Z","timestamp":1646620443000},"source":"Crossref","is-referenced-by-count":6,"title":["Relation Between Renin\u2013Angiotensin\u2013Aldosterone System Inhibitors and COVID-19 Severity"],"prefix":"10.7759","author":[{"given":"Mousa J","family":"Alhaddad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed S","family":"Almulaify","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah A","family":"Alshabib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albatool A","family":"Alwesaibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed A","family":"Alkhameys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zainab K","family":"Alsenan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hawra J","family":"Alsheef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed A","family":"Alsaghirat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed S","family":"Almomtan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marai N","family":"Alshakhs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000000722","article-title":"Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study","volume":"133","author":"Ren LL","year":"2020","unstructured":"Ren LL, Wang YM, Wu ZQ, et al.. Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study. Chin Med J (Engl). 2020, 133:1015-24. 10.1097\/CM9.0000000000000722","journal-title":"Chin Med J (Engl)"},{"key":"ref2","unstructured":"World Health Organization. WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020. (2020). Accessed: February 23, 2022: https:\/\/www.who.int\/director-general\/speeches\/detail\/who-director-general-s-opening-remarks-at-the-media-briefing-on-...."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00127-20","article-title":"Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus","volume":"94","author":"Wan Y","year":"2020","unstructured":"Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. J Virol. 2020, 94:10.1128\/JVI.00127-20","journal-title":"J Virol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann M","year":"2020","unstructured":"Hoffmann M, Kleine-Weber H, Schroeder S, et al.. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020, 181:271-280.e8. 10.1016\/j.cell.2020.02.052","journal-title":"Cell"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30116-8","article-title":"Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?","volume":"8","author":"Fang L","year":"2020","unstructured":"Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?. Lancet Respir Med. 2020, 8:e21. 10.1016\/S2213-2600(20)30116-8","journal-title":"Lancet Respir Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.90488.2008","article-title":"Localization of ACE2 in the renal vasculature: amplification by angiotensin II type 1 receptor blockade using telmisartan","volume":"296","author":"Soler MJ","year":"2009","unstructured":"Soler MJ, Ye M, Wysocki J, William J, Lloveras J, Batlle D. Localization of ACE2 in the renal vasculature: amplification by angiotensin II type 1 receptor blockade using telmisartan. Am J Physiol Renal Physiol. 2009, 296:F398-405. 10.1152\/ajprenal.90488.2008","journal-title":"Am J Physiol Renal Physiol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/jtm\/taaa041","article-title":"Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19","volume":"27","author":"Diaz JH","year":"2020","unstructured":"Diaz JH. Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19. J Travel Med. 2020, 27:10.1093\/jtm\/taaa041","journal-title":"J Travel Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.765951","article-title":"Effect of angiotensin-converting-enzyme inhibitor and angiotensin II receptor antagonist treatment on ACE2 expression and SARS-CoV-2 replication in primary airway epithelial cells","volume":"12","author":"Okoloko O","year":"2021","unstructured":"Okoloko O, Vanderwall ER, Rich LM, et al.. Effect of angiotensin-converting-enzyme inhibitor and angiotensin II receptor antagonist treatment on ACE2 expression and SARS-CoV-2 replication in primary airway epithelial cells. Front Pharmacol. 2021, 12:765951. 10.3389\/fphar.2021.765951","journal-title":"Front Pharmacol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2022.120324","article-title":"Renin-angiotensin system blockade on angiotensin-converting enzyme 2 and TMPRSS2 in human type II pneumocytes","volume":"293","author":"Silva MG","year":"2022","unstructured":"Silva MG, Falcoff NL, Corradi GR, et al.. Renin-angiotensin system blockade on angiotensin-converting enzyme 2 and TMPRSS2 in human type II pneumocytes. Life Sci. 2022, 293:120324. 10.1016\/j.lfs.2022.120324","journal-title":"Life Sci"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2020.1746200","article-title":"Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension","volume":"9","author":"Meng J","year":"2020","unstructured":"Meng J, Xiao G, Zhang J, et al.. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. Emerg Microbes Infect. 2020, 9:757-60. 10.1080\/22221751.2020.1746200","journal-title":"Emerg Microbes Infect"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.120.15143","article-title":"Effects of angiotensin II receptor blockers and ACE (angiotensin-converting enzyme) inhibitors on virus infection, inflammatory status, and clinical outcomes in patients with COVID-19 and hypertension: a single-center retrospective study","volume":"76","author":"Yang G","year":"2020","unstructured":"Yang G, Tan Z, Zhou L, et al.. Effects of angiotensin II receptor blockers and ACE (angiotensin-converting enzyme) inhibitors on virus infection, inflammatory status, and clinical outcomes in patients with COVID-19 and hypertension: a single-center retrospective study. Hypertension. 2020, 76:51-8. 10.1161\/HYPERTENSIONAHA.120.15143","journal-title":"Hypertension"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.11122","article-title":"Assessment of hypokalemia and clinical characteristics in patients with coronavirus disease 2019 in Wenzhou, China","volume":"3","author":"Chen D","year":"2020","unstructured":"Chen D, Li X, Song Q, et al.. Assessment of hypokalemia and clinical characteristics in patients with coronavirus disease 2019 in Wenzhou, China. JAMA Netw Open. 2020, 3:e2011122. 10.1001\/jamanetworkopen.2020.11122","journal-title":"JAMA Netw Open"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab697","article-title":"ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up","year":"2021","unstructured":"ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic. part 2-care pathways, treatment, and follow-up. Eur Heart J. 2021, 10.1093\/eurheartj\/ehab697","journal-title":"Eur Heart J"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/s41440-020-0515-0","article-title":"Hypertension and related diseases in the era of COVID-19: a report from the Japanese Society of Hypertension Task Force on COVID-19","volume":"43","author":"Shibata S","year":"2020","unstructured":"Shibata S, Arima H, Asayama K, et al.. Hypertension and related diseases in the era of COVID-19: a report from the Japanese Society of Hypertension Task Force on COVID-19. Hypertens Res. 2020, 43:1028-46. 10.1038\/s41440-020-0515-0","journal-title":"Hypertens Res"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/s41371-020-00451-x","article-title":"COVID-19 and hypertension: risks and management. A scientific statement on behalf of the British and Irish Hypertension Society","volume":"35","author":"Clark CE","year":"2021","unstructured":"Clark CE, McDonagh ST, McManus RJ, Martin U. COVID-19 and hypertension: risks and management. A scientific statement on behalf of the British and Irish Hypertension Society. J Hum Hypertens. 2021, 35:304-7. 10.1038\/s41371-020-00451-x","journal-title":"J Hum Hypertens"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.25864","article-title":"Effect of discontinuing vs continuing angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on days alive and out of the hospital in patients admitted with COVID-19: a randomized clinical trial","volume":"325","author":"Lopes RD","year":"2021","unstructured":"Lopes RD, Macedo AV, de Barros E Silva PG, et al.. Effect of discontinuing vs continuing angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on days alive and out of the hospital in patients admitted with COVID-19: a randomized clinical trial. JAMA. 2021, 325:254-64. 10.1001\/jama.2020.25864","journal-title":"JAMA"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s40292-021-00462-w","article-title":"Safety and efficacy of renin-angiotensin-aldosterone system inhibitors in COVID-19 population","volume":"28","author":"Sattar Y","year":"2021","unstructured":"Sattar Y, Mukuntharaj P, Zghouzi M, et al.. Safety and efficacy of renin-angiotensin-aldosterone system inhibitors in COVID-19 population. High Blood Press Cardiovasc Prev. 2021, 28:405-16. 10.1007\/s40292-021-00462-w","journal-title":"High Blood Press Cardiovasc Prev"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.703661","article-title":"Mortality and severity in COVID-19 patients on ACEIs and ARBs-a systematic review, meta-analysis, and meta-regression analysis","volume":"8","author":"Singh R","year":"2021","unstructured":"Singh R, Rathore SS, Khan H, et al.. Mortality and severity in COVID-19 patients on ACEIs and ARBs-a systematic review, meta-analysis, and meta-regression analysis. Front Med (Lausanne). 2021, 8:703661. 10.3389\/fmed.2021.703661","journal-title":"Front Med (Lausanne)"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.26625","article-title":"The use of renin-angiotensin-aldosterone system (RAAS) inhibitors is associated with a lower risk of mortality in hypertensive COVID-19 patients: a systematic review and meta-analysis","volume":"93","author":"Wang Y","year":"2021","unstructured":"Wang Y, Chen B, Li Y, et al.. The use of renin-angiotensin-aldosterone system (RAAS) inhibitors is associated with a lower risk of mortality in hypertensive COVID-19 patients: a systematic review and meta-analysis. J Med Virol. 2021, 93:1370-7. 10.1002\/jmv.26625","journal-title":"J Med Virol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.21037\/apm-21-972","article-title":"The divergent protective effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on clinical outcomes of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis","author":"Xie Q","year":"2021","unstructured":"Xie Q, Tang S, Li Y. The divergent protective effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on clinical outcomes of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. Ann Palliat Med. 2021, 10.21037\/apm-21-972","journal-title":"Ann Palliat Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.2015","article-title":"Association between baseline use of angiotensin-converting enzyme inhibitors and angiotensin\u00a0receptor blockers and death among patients tested for COVID-19","author":"Thomas SA","year":"2021","unstructured":"Thomas SA, Puskarich M, Pulia MS, et al.. Association between baseline use of angiotensin-converting enzyme inhibitors and angiotensin\u00a0receptor blockers and death among patients tested for COVID-19. J Clin Pharmacol. 2021, 10.1002\/jcph.2015","journal-title":"J Clin Pharmacol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3390\/jcdd9010015","article-title":"Renin angiotensin system blockers and risk of mortality in hypertensive patients hospitalized for COVID-19: an Italian registry","volume":"9","author":"Angeli F","year":"2022","unstructured":"Angeli F, Verdecchia P, Balestrino A, et al.. Renin angiotensin system blockers and risk of mortality in hypertensive patients hospitalized for COVID-19: an Italian registry. J Cardiovasc Dev Dis. 2022, 9:10.3390\/jcdd9010015","journal-title":"J Cardiovasc Dev Dis"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfab161","article-title":"Association of renin-angiotensin system blockers with COVID-19 diagnosis and prognosis in patients with hypertension: a population-based study","volume":"15","author":"Soler MJ","year":"2022","unstructured":"Soler MJ, Ribera A, Marsal JR, et al.. Association of renin-angiotensin system blockers with COVID-19 diagnosis and prognosis in patients with hypertension: a population-based study. Clin Kidney J. 2022, 15:79-94. 10.1093\/ckj\/sfab161","journal-title":"Clin Kidney J"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15192","article-title":"Association of renin-angiotensin-aldosterone system inhibition with Covid-19 hospitalization and all-cause mortality in the UK biobank","author":"Safizadeh F","year":"2021","unstructured":"Safizadeh F, Nguyen TN, Brenner H, Sch\u00f6ttker B. Association of renin-angiotensin-aldosterone system inhibition with Covid-19 hospitalization and all-cause mortality in the UK biobank. Br J Clin Pharmacol. 2021, 10.1111\/bcp.15192","journal-title":"Br J Clin Pharmacol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa677","article-title":"Long-term ACE inhibitor\/ARB use is associated with severe renal dysfunction and acute kidney injury in patients with severe COVID-19: results from a referral center cohort in the northeast of France","volume":"71","author":"Oussalah A","year":"2020","unstructured":"Oussalah A, Gleye S, Clerc Urmes I, et al.. Long-term ACE inhibitor\/ARB use is associated with severe renal dysfunction and acute kidney injury in patients with severe COVID-19: results from a referral center cohort in the northeast of France. Clin Infect Dis. 2020, 71:2447-56. 10.1093\/cid\/ciaa677","journal-title":"Clin Infect Dis"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-92323-8","article-title":"Increased risk of acute kidney injury in coronavirus disease patients with renin-angiotensin-aldosterone-system blockade use: a systematic review and meta-analysis","volume":"11","author":"Lee SA","year":"2021","unstructured":"Lee SA, Park R, Yang JH, et al.. Increased risk of acute kidney injury in coronavirus disease patients with renin-angiotensin-aldosterone-system blockade use: a systematic review and meta-analysis. Sci Rep. 2021, 11:13588. 10.1038\/s41598-021-92323-8","journal-title":"Sci Rep"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/89093-relation-between-renin-angiotensin-aldosterone-system-inhibitors-and-covid-19-severity","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:41:53Z","timestamp":1707507713000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/89093-relation-between-renin-angiotensin-aldosterone-system-inhibitors-and-covid-19-severity"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,6]]},"references-count":26,"URL":"https:\/\/doi.org\/10.7759\/cureus.22903","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3,6]]}}}